DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk
Prostate-specific antigen (PSA) and other biomarkers are essential tools for diagnosing and monitoring prostate cancer. However, biomarkers to selectively identify patients with high risk of recurrence, those who might benefit from intervention, and those who can safely choose active surveillance, are lacking. A report describes a biomarker, PITX2 DNA methylation, which is capable of distinguishing […]
